CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER
<p>Chemotherapy with docetaxel (Taxotere) used alone or in combination with other agents is today the standard of treatment for metastatic hormone refractory prostate cancer (HRPC). Nevertheless, there remain many unsolved problems associated with its use. A search for drugs, their combination...
Main Author: | O. B. Karyakin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | http://oncourology.abvpress.ru/index.php/oncur/article/view/120 |
Similar Items
-
CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER
by: O. B. Karyakin
Published: (2014-07-01) -
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
by: Kai-Jie Wu, et al.
Published: (2018-01-01) -
The Effect of Multiplicity of Metastatic Sites on Hormone Refractory Prostate Cancer
by: Amal Halim
Published: (2012-10-01) -
BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01) -
BEAM THERAPY AND LONG-TERM HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: A. O. Karyakin, et al.
Published: (2014-07-01)